Elucidation of anti-SARS-CoV-2 and anti-inflammatory bioactives in Qingyan Dropping Pills via integrated in silico screening and bioactivity validation
Our study focused on Chinese patent medicine QDP to highlight the anti-SARS-CoV-2 and anti-inflammatory bioactives, providing evidence and insights into its clinical practice in the treatment of COVID-19.
Authors
- Jing Yang (ORCID: https://orcid.org/0000-0003-1221-7429)
- Liting Liu (ORCID: https://orcid.org/0000-0002-5463-4821)
- Yuefei Wang
- Peng Zhang (ORCID: https://orcid.org/0000-0002-3281-3757)
- Junhua Zhang (ORCID: https://orcid.org/0000-0003-4043-1967)
- Min Zhang (ORCID: https://orcid.org/0000-0003-1938-2902)
- Tong Geng
- Qi Yang (ORCID: https://orcid.org/0000-0002-2067-3195)
- Xinru Li (ORCID: https://orcid.org/0000-0003-4846-9193)
- Changjian Wang (ORCID: https://orcid.org/0000-0003-2745-7628)
- Xinyue Wang (ORCID: https://orcid.org/0009-0005-7881-1692)
Institutions
- Tianjin University of Traditional Chinese Medicine (CN)
- Tianjin Institute of Pharmaceutical Research (China) (CN)
- Tianjin haihe hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-11-10
- DOI
- https://doi.org/10.3389/fmed.2025.1684713
- Primary Topic
- Andrographolide Research and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Tianjin University
- Tianjin University of Science and Technology